Episode 3 of 3 - Help Your Patients Navigate Risk-benefit Assessment, Choose the Best Therapy for Them, and Mitigate TEAEs

In the advent of novel targeted therapies for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), clinicians must consider the potential of adverse events (AEs) that can affect patient outcomes. In the last episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement, our expert faculty will engage in an interactive discussion on AE-management to promote optimal treatment-decision making for clinicians. In addition, learn tips to on how to counsel your patients on monitoring their symptoms to support timely and effective care.